A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Must have received:

For non-PCNSL indications, received at least 2 prior lines of therapy and have no other available therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy

Cannot have received: radiation therapy

Exception: excluding limited palliative radiation

Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)

Cannot have received: systemic chemotherapy

Prior systemic chemotherapy within 2 weeks of planned start of study drug

Cannot have received: monoclonal antibody

Exception: Cohort 16 (CLL with secondary wAIHA) requires 16-week washout

Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week washout period is required

Cannot have received: small molecule therapy

Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug

Cannot have received: autologous stem cell transplant

Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug

Cannot have received: allogeneic stem cell transplant

Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug

Cannot have received: CAR-T cell therapy

Exception: within 60 days for Phase 1b

Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b)

Cannot have received: BTK degrader

Previously treated with a BTK degrader